Information

Related Research Units

Nephrology Research

Research Overview

Dr. Fiorina’s research focuses on diabetes. In particular, he is interested in three major areas: (1) the treatment of autoimmune diabetes; (2) the replacement of beta cells through islet transplantation; (3) the treatment of diabetic nephropathy. Dr. Fiorina has made significant and innovative contributions in understanding the mechanism underlying the beneficial effects of life expectancy obtained after islet transplantation, even when patients only have partial islet function.

Research Background

Dr. Paolo Fiorina obtained his medical degree from the University of Milan and continued his training at the combined Internal Medicine/PhD program in immunology at Parma University. After studying transplantation immunology for six years at the San Raffaele Scientific Institute in Milan, one of the leading programs in human islet cell transplantation, Dr. Fiorina joined Boston Children's Hospital as a research fellow in 2004. In 2009 he became an Assistant Professor of Nephrology at Boston Children’s/Harvard Medical School.

Publications

  1. A multi-omics integration approach relying on circulating factors does not discern subtypes of childhood type 1 diabetes. Commun Med (Lond). 2025 May 27; 5(1):201. View Abstract
  2. TMEM219 signaling promotes intestinal stem cell death and exacerbates colitis. J Clin Invest. 2025 May 15; 135(10). View Abstract
  3. Vital Sign and Biochemical Data Collection Using Non-contact Photoplethysmography and the Comestai Mobile Health App: Protocol for an Observational Study. JMIR Res Protoc. 2025 Apr 28; 14:e65229. View Abstract
  4. Vaccinome Landscape in Nearly 620 000 Patients With Diabetes. J Clin Endocrinol Metab. 2025 Apr 22; 110(5):e1590-e1597. View Abstract
  5. Correction: Importance of Donor-Derived and Recipient-Derived Selectins in Cardiac Allograft Rejection. J Am Soc Nephrol. 2025 Apr 10. View Abstract
  6. Best practices in islet transplantation in mice. Am J Transplant. 2025 Mar 13. View Abstract
  7. Metabolic phenotype of Stage 1 and Stage 2 type 1 diabetes using modelling of beta cell function. J Clin Endocrinol Metab. 2025 Feb 24. View Abstract
  8. Pharmacological regression of atherosclerotic plaque in patients with type 2 diabetes. Pharmacol Res. 2025 Mar; 213:107635. View Abstract
  9. Non-parathyroid hypercalcemia in a patient with new-onset hyperthyroidism and silicone-induced granulomas: case report. Front Endocrinol (Lausanne). 2024; 15:1447652. View Abstract
  10. Glucose metrics and device satisfaction in adults with type 1 diabetes using different treatment modalities: a multicenter, real-world observational study. Acta Diabetol. 2025 Apr; 62(4):563-573. View Abstract
  11. Immune-Mediated Inflammatory Diseases and Cancer - a dangerous liaison. Front Immunol. 2024; 15:1436581. View Abstract
  12. A new glucose monitoring system for the intermittent monitoring of interstitial glucose values in patients with diabetes mellitus. J Diabetes Metab Disord. 2024 Dec; 23(2):2201-2205. View Abstract
  13. Long-term cytokine profile in multisystem inflammatory disease among children. Cytokine. 2024 Nov; 183:156744. View Abstract
  14. Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule. Cell Metab. 2024 Jun 04; 36(6):1302-1319.e12. View Abstract
  15. Post-Transplant Diabetes Mellitus in Kidney-Transplanted Patients: Related Factors and Impact on Long-Term Outcome. Nutrients. 2024 May 17; 16(10). View Abstract
  16. Hyperglycemia impairs EAAT2 glutamate transporter trafficking and glutamate clearance in islets of Langerhans: implications for type 2 diabetes pathogenesis and treatment. Am J Physiol Endocrinol Metab. 2024 Jul 01; 327(1):E27-E41. View Abstract
  17. TMEM219 regulates the transcription factor expression and proliferation of beta cells. Front Endocrinol (Lausanne). 2024; 15:1306127. View Abstract
  18. Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide. Pharmacol Res. 2024 Jan; 199:107040. View Abstract
  19. Daytime hypoglycemic episodes during the use of an advanced hybrid closed loop system. Diabetes Res Clin Pract. 2023 Dec; 206:111011. View Abstract
  20. Reversal of Experimental Autoimmune Diabetes With an sCD39/Anti-CD3 Treatment. Diabetes. 2023 Nov 01; 72(11):1641-1651. View Abstract
  21. Early lung diffusion abnormalities and airways' inflammation in children with type 1 diabetes. Acta Diabetol. 2024 Mar; 61(3):289-295. View Abstract
  22. Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets. Am J Physiol Endocrinol Metab. 2023 11 01; 325(5):E595-E609. View Abstract
  23. Nanotargeted Delivery of Immune Therapeutics in Type 1 Diabetes. Adv Mater. 2023 Oct; 35(40):e2300812. View Abstract
  24. The anti-inflammatory and immunological properties of SGLT-2 inhibitors. J Endocrinol Invest. 2023 Dec; 46(12):2445-2452. View Abstract
  25. Long-Term Activity and Safety of a Low-Dose Hydrocortisone Tear Substitute in Patients with Dry Eye Disease. Curr Eye Res. 2023 09; 48(9):799-804. View Abstract
  26. AWARE A novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitus. Acta Diabetol. 2023 Sep; 60(9):1257-1266. View Abstract
  27. Increased Risk of Diabetes and Diabetic Ketoacidosis Associated With COVID-19. Diabetes. 2023 05 01; 72(5):560-561. View Abstract
  28. Targeting a novel apoptotic pathway in human disease. Bioessays. 2023 06; 45(6):e2200231. View Abstract
  29. Broadening horizons in mechanisms, management, and treatment of diabetic kidney disease. Pharmacol Res. 2023 04; 190:106710. View Abstract
  30. eATP and autoimmune diabetes. Pharmacol Res. 2023 04; 190:106709. View Abstract
  31. Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01). Front Endocrinol (Lausanne). 2022; 13:1099451. View Abstract
  32. Efficacy of mucosal vaccination using a protozoan parasite as a vehicle for antigen delivery: IgG and neutralizing response after rectal administration of LeCoVax-2, a candidate vaccine against COVID-19. Pharmacol Res. 2022 12; 186:106546. View Abstract
  33. Benefits and Hurdles of Pancreatic ß-Cell Replacement. Stem Cells Transl Med. 2022 Oct 21; 11(10):1029-1039. View Abstract
  34. Antigen-based Immunotherapy Improves Glycemic Metrics and ß-Cell Function. J Clin Endocrinol Metab. 2022 09 28; 107(10):e4250-e4251. View Abstract
  35. Response to Comment on D'Addio et al. Immunogenicity and Safety of SARS-CoV-2 mRNA Vaccines in a Cohort of Patients With Type 1 Diabetes. Diabetes 2022;71:1800-1806. Diabetes. 2022 09 01; 71(9):e14. View Abstract
  36. SGLT2-inhibitors are effective and safe in the elderly: The SOLD study. Pharmacol Res. 2022 09; 183:106396. View Abstract
  37. Neuroblastoma suppressor of tumorigenicity 1 is a circulating protein associated with progression to end-stage kidney disease in diabetes. Sci Transl Med. 2022 08 10; 14(657):eabj2109. View Abstract
  38. Immunogenicity and Safety of SARS-CoV-2 mRNA Vaccines in a Cohort of Patients With Type 1 Diabetes. Diabetes. 2022 08 01; 71(8):1800-1806. View Abstract
  39. Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study. Pharmacol Res. 2022 09; 183:106374. View Abstract
  40. Inflammation and vascular dysfunction: The negative synergistic combination of diabetes and COVID-19. Diabetes Metab Res Rev. 2022 10; 38(7):e3565. View Abstract
  41. Indirect and Direct Effects of SARS-CoV-2 on Human Pancreatic Islets. Diabetes. 2022 07 01; 71(7):1579-1590. View Abstract
  42. Abnormalities of the oculomotor function in type 1 diabetes and diabetic neuropathy. Acta Diabetol. 2022 Sep; 59(9):1157-1167. View Abstract
  43. The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists. Pharmacol Res. 2022 08; 182:106320. View Abstract
  44. Unveiling a novel type 1 diabetes endotype: Opportunities for intervention. Diabetes Metab Res Rev. 2022 07; 38(5):e3536. View Abstract
  45. Should we expect a wave of type 1 diabetes following SARS-CoV-2 pandemic? Diabetes Metab Res Rev. 2022 05; 38(4):e3529. View Abstract
  46. Hybrid Close-Loop Systems Versus Predictive Low-Glucose Suspend and Sensor-Augmented Pump Therapy in Patients With Type 1 Diabetes: A Single-Center Cohort Study. Front Endocrinol (Lausanne). 2022; 13:816599. View Abstract
  47. Liraglutide preserves CD34+ stem cells from dysfunction Induced by high glucose exposure. Cardiovasc Diabetol. 2022 04 09; 21(1):51. View Abstract
  48. One year of Hybrid Closed Loop on peritoneal dialysis: a case report. Acta Diabetol. 2022 Jul; 59(7):985-988. View Abstract
  49. Pharmacologically Enhanced Regulatory Hematopoietic Stem Cells Revert Experimental Autoimmune Diabetes and Mitigate Other Autoimmune Disorders. J Immunol. 2022 04 01; 208(7):1554-1565. View Abstract
  50. Novel Soluble Mediators of Innate Immune System Activation in Solid Allograft Rejection. Transplantation. 2022 03 01; 106(3):500-509. View Abstract
  51. Autoantibodies against the glial glutamate transporter GLT1/EAAT2 in Type 1 diabetes mellitus-Clues to novel immunological and non-immunological therapies. Pharmacol Res. 2022 03; 177:106130. View Abstract
  52. The IGFBP3/TMEM219 pathway regulates beta cell homeostasis. Nat Commun. 2022 02 03; 13(1):684. View Abstract
  53. Characterization of Leptin Receptor+ Stromal Cells in Lymph Node. Front Immunol. 2021; 12:730438. View Abstract
  54. Kidney-Draining Lymph Node Fibrosis Following Unilateral Ureteral Obstruction. Front Immunol. 2021; 12:768412. View Abstract
  55. PD-1 blockade counteracts post-COVID-19 immune abnormalities and stimulates the anti-SARS-CoV-2 immune response. JCI Insight. 2021 12 22; 6(24). View Abstract
  56. Imaging in experimental models of diabetes. Acta Diabetol. 2022 Feb; 59(2):147-161. View Abstract
  57. Editorial: The Role of Hematopoietic Progenitors in Immune Regulation and Memory. Front Immunol. 2021; 12:789139. View Abstract
  58. Next-gen therapeutics to spare and expand beta-cell mass. Curr Opin Pharmacol. 2021 12; 61:77-82. View Abstract
  59. Anti-diabetic drugs and weight loss in patients with type 2 diabetes. Pharmacol Res. 2021 09; 171:105782. View Abstract
  60. Prevalence and significance of mesentery thickening and lymph nodes enlargement in Crohn's disease. Dig Liver Dis. 2022 Apr; 54(4):490-499. View Abstract
  61. Hematopoietic Stem Cells in Type 1 Diabetes. Front Immunol. 2021; 12:694118. View Abstract
  62. ACTH treatment promotes murine cardiac allograft acceptance. JCI Insight. 2021 07 08; 6(13). View Abstract
  63. The IL-8-CXCR1/2 axis contributes to diabetic kidney disease. Metabolism. 2021 08; 121:154804. View Abstract
  64. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat Metab. 2021 06; 3(6):774-785. View Abstract
  65. Targeted Blood Brain Barrier Opening With Focused Ultrasound Induces Focal Macrophage/Microglial Activation in Experimental Autoimmune Encephalomyelitis. Front Neurosci. 2021; 15:665722. View Abstract
  66. miR-21 antagonism reprograms macrophage metabolism and abrogates chronic allograft vasculopathy. Am J Transplant. 2021 10; 21(10):3280-3295. View Abstract
  67. Polypill in Persons without Cardiovascular Disease. N Engl J Med. 2021 04 29; 384(17):1673-1674. View Abstract
  68. REL-1017 (Esmethadone) Increases Circulating BDNF Levels in Healthy Subjects of a Phase 1 Clinical Study. Front Pharmacol. 2021; 12:671859. View Abstract
  69. How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group. Front Immunol. 2021; 12:656362. View Abstract
  70. Continuous glucose monitoring in patients with type 2 diabetes on hemodialysis. Acta Diabetol. 2021 Aug; 58(8):975-981. View Abstract
  71. Regulatory B Cells in Autoimmune Diabetes. J Immunol. 2021 03 15; 206(6):1117-1125. View Abstract
  72. Anti-inflammatory effects of diet and caloric restriction in metabolic syndrome. J Endocrinol Invest. 2021 Nov; 44(11):2407-2415. View Abstract
  73. Strictureplasties performed by laparoscopic approach for complicated Crohn's disease. A prospective, observational, cohort study. Dig Liver Dis. 2021 Oct; 53(10):1286-1293. View Abstract
  74. Simultaneous targeting of primary tumor, draining lymph node, and distant metastases through high endothelial venule-targeted delivery. Nano Today. 2021 Feb; 36. View Abstract
  75. Reply to letter to the editor regarding "Use of DPP-4 inhibitors in patients with COVID-19". Acta Diabetol. 2021 02; 58(2):247-248. View Abstract
  76. Rice flour fermented with Lactobacillus paracasei CBA L74 in the treatment of atopic dermatitis in infants: A randomized, double- blind, placebo- controlled trial. Pharmacol Res. 2021 01; 163:105284. View Abstract
  77. Selective Trafficking of Light Chain-Conjugated Nanoparticles to the Kidney and Renal Cell Carcinoma. Nano Today. 2020 Dec; 35. View Abstract
  78. Placental proteome abnormalities in women with gestational diabetes and large-for-gestational-age newborns. BMJ Open Diabetes Res Care. 2020 11; 8(2). View Abstract
  79. Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study. Diabetes Care. 2020 12; 43(12):2999-3006. View Abstract
  80. Lymph node fibroblastic reticular cells deposit fibrosis-associated collagen following organ transplantation. J Clin Invest. 2020 08 03; 130(8):4182-4194. View Abstract
  81. The Impact of Diabetes Mellitus on Cardiovascular Risk Onset in Children and Adolescents. Int J Mol Sci. 2020 Jul 12; 21(14). View Abstract
  82. Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists. Pharmacol Res. 2020 10; 160:105052. View Abstract
  83. Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes. Pharmacol Res. 2020 09; 159:104996. View Abstract
  84. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. Acta Diabetol. 2020 Jul; 57(7):779-783. View Abstract
  85. Cell therapy for type 1 diabetes. Expert Opin Biol Ther. 2020 08; 20(8):887-897. View Abstract
  86. Embryonic stem cell extracts improve wound healing in diabetic mice. Acta Diabetol. 2020 Jul; 57(7):883-890. View Abstract
  87. Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune response. J Clin Invest. 2019 12 02; 129(12):5518-5536. View Abstract
  88. Exenatide regulates pancreatic islet integrity and insulin sensitivity in the nonhuman primate baboon Papio hamadryas. JCI Insight. 2019 10 17; 4(20). View Abstract
  89. Sitagliptin favorably modulates immune-relevant pathways in human beta cells. Pharmacol Res. 2019 10; 148:104405. View Abstract
  90. Immune heterogeneity of head and tail pancreatic lymph nodes in non-obese diabetic mice. Sci Rep. 2019 07 05; 9(1):9778. View Abstract
  91. The ß-cell effect of verapamil-based treatment in patients with type 2 diabetes: a systematic review. Acta Diabetol. 2020 Feb; 57(2):117-131. View Abstract
  92. A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. Nat Med. 2019 05; 25(5):805-813. View Abstract
  93. Duodenal adipose tissue is associated with obesity in baboons (Papio sp): a novel site of ectopic fat deposition in non-human primates. Acta Diabetol. 2019 Feb; 56(2):227-236. View Abstract
  94. Idebenone and T2D: A new insulin-sensitizing drug for personalized therapy. Pharmacol Res. 2019 01; 139:469-470. View Abstract
  95. The impact of a successful treatment of hepatitis C virus on glyco-metabolic control in diabetic patients: a systematic review and meta-analysis. Acta Diabetol. 2019 Mar; 56(3):341-354. View Abstract
  96. Islet-Derived eATP Fuels Autoreactive CD8+ T Cells and Facilitates the Onset of Type 1 Diabetes. Diabetes. 2018 10; 67(10):2038-2053. View Abstract
  97. Covered stenting and transcatheter embolization of splenic artery aneurysms in diabetic patients: A review of endovascular treatment of visceral artery aneurysms in the current era. Pharmacol Res. 2018 09; 135:127-135. View Abstract
  98. P2X7R mutation disrupts the NLRP3-mediated Th program and predicts poor cardiac allograft outcomes. J Clin Invest. 2018 08 01; 128(8):3490-3503. View Abstract
  99. Repetitive ischemic injuries to the kidneys result in lymph node fibrosis and impaired healing. JCI Insight. 2018 07 12; 3(13). View Abstract
  100. Prostaglandin E2 Stimulates the Expansion of Regulatory Hematopoietic Stem and Progenitor Cells in Type 1 Diabetes. Front Immunol. 2018; 9:1387. View Abstract
  101. Totally laparoscopic, multi-stage, restorative proctocolectomy for inflammatory bowel diseases. A prospective study on safety, efficacy and long-term results. Dig Liver Dis. 2018 12; 50(12):1283-1291. View Abstract
  102. Sodium glucose cotransporters inhibitors in type 1 diabetes. Pharmacol Res. 2018 07; 133:1-8. View Abstract
  103. Allo- and auto-percutaneous intra-portal pancreatic islet transplantation (PIPIT) for diabetes cure and prevention: the role of imaging and interventional radiology. Gland Surg. 2018 Apr; 7(2):117-131. View Abstract
  104. Ischemia augments alloimmune injury through IL-6-driven CD4+ alloreactivity. Sci Rep. 2018 02 06; 8(1):2461. View Abstract
  105. ATP and T-cell-mediated rejection. Curr Opin Organ Transplant. 2018 02; 23(1):34-43. View Abstract
  106. Noninvasive induction of angiogenesis in tissues by external suction: sequential optimization for use in reconstructive surgery. Angiogenesis. 2018 02; 21(1):61-78. View Abstract
  107. PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes. Sci Transl Med. 2017 Nov 15; 9(416). View Abstract
  108. Adipose Stem Cell Therapy for Chronic Pancreatitis. Mol Ther. 2017 11 01; 25(11):2438-2439. View Abstract
  109. Immunotherapy for type 1 diabetes. J Endocrinol Invest. 2017 Aug; 40(8):803-814. View Abstract
  110. Targeting Immunity in End-Stage Renal Disease. Am J Nephrol. 2017; 45(4):310-319. View Abstract
  111. Immunoevasion rather than intrinsic oncogenicity may confer MSCs from non-obese diabetic mice the ability to generate neural tumors. Acta Diabetol. 2017 Jul; 54(7):707-712. View Abstract
  112. Metabolomic Profiling in Individuals with a Failing Kidney Allograft. PLoS One. 2017; 12(1):e0169077. View Abstract
  113. CXCR4 antagonism overcomes diabetic stem cell mobilopathy. Atherosclerosis. 2016 08; 251:512-513. View Abstract
  114. Type 1 Diabetes and Dysfunctional Intestinal Homeostasis. Trends Endocrinol Metab. 2016 07; 27(7):493-503. View Abstract
  115. The use of hematopoietic stem cells in autoimmune diseases. Regen Med. 2016 06; 11(4):395-405. View Abstract
  116. Circulating IGF-I and IGFBP3 Levels Control Human Colonic Stem Cell Function and Are Disrupted in Diabetic Enteropathy. Cell Stem Cell. 2015 10 01; 17(4):486-498. View Abstract
  117. CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease. Diabetologia. 2016 Jan; 59(1):21-29. View Abstract
  118. Explaining the increased mortality in type 1 diabetes. World J Diabetes. 2015 Jul 10; 6(7):889-95. View Abstract
  119. PI3ka and STAT1 Interplay Regulates Human Mesenchymal Stem Cell Immune Polarization. Stem Cells. 2015 Jun; 33(6):1892-901. View Abstract
  120. Novel therapies for T1D on the horizon. Pharmacol Res. 2015 Aug; 98:1-2. View Abstract
  121. Co-transplantation of autologous MSCs delays islet allograft rejection and generates a local immunoprivileged site. Acta Diabetol. 2015 Oct; 52(5):917-27. View Abstract
  122. Hepatic steatosis after islet transplantation: Can ultrasound predict the clinical outcome? A longitudinal study in 108 patients. Pharmacol Res. 2015 Aug; 98:52-9. View Abstract
  123. ROCK-isoform-specific polarization of macrophages associated with age-related macular degeneration. Cell Rep. 2015 Feb 24; 10(7):1173-86. View Abstract
  124. P2X receptors and diabetes. Curr Med Chem. 2015; 22(7):891-901. View Abstract
  125. Novel therapeutic and diagnostic management of heart transplant patients. Heart Lung Vessel. 2015; 7(3):198-207. View Abstract
  126. The dark side of extracellular ATP in kidney diseases. J Am Soc Nephrol. 2015 May; 26(5):1007-16. View Abstract
  127. Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates. Am J Pathol. 2015 Jan; 185(1):139-50. View Abstract
  128. Interleukin-10+ regulatory B cells arise within antigen-experienced CD40+ B cells to maintain tolerance to islet autoantigens. Diabetes. 2015 Jan; 64(1):158-71. View Abstract
  129. Kidney transplantation in children. N Engl J Med. 2014 Aug 07; 371(6):549-58. View Abstract
  130. The rise, fall, and resurgence of immunotherapy in type 1 diabetes. Pharmacol Res. 2015 Aug; 98:31-8. View Abstract
  131. Inhibition of the purinergic pathway prolongs mouse lung allograft survival. Am J Respir Cell Mol Biol. 2014 Aug; 51(2):300-10. View Abstract
  132. Novel immunological strategies for islet transplantation. Pharmacol Res. 2015 Aug; 98:69-75. View Abstract
  133. Autologous nonmyeloablative hematopoietic stem cell transplantation in new-onset type 1 diabetes: a multicenter analysis. Diabetes. 2014 Sep; 63(9):3041-6. View Abstract
  134. Harnessing the immunological properties of stem cells as a therapeutic option for diabetic nephropathy. Acta Diabetol. 2014 Dec; 51(6):897-904. View Abstract
  135. Role of podocyte B7-1 in diabetic nephropathy. J Am Soc Nephrol. 2014 Jul; 25(7):1415-29. View Abstract
  136. The mechanisms of up-regulation of dendritic cell activity by oxidative stress. J Leukoc Biol. 2014 Aug; 96(2):283-93. View Abstract
  137. Positive effects of a novel non-peptidyl low molecular weight radical scavenger in renal ischemia/reperfusion: a preliminary report. Springerplus. 2014; 3:158. View Abstract
  138. TIM4 Regulates the Anti-Islet Th2 Alloimmune Response. Cell Transplant. 2015; 24(8):1599-1614. View Abstract
  139. The purinergic system in allotransplantation. Am J Transplant. 2014 Mar; 14(3):507-14. View Abstract
  140. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med. 2013 Dec 19; 369(25):2416-23. View Abstract
  141. GABAergic system in ß-cells: from autoimmunity target to regeneration tool. Diabetes. 2013 Nov; 62(11):3674-6. View Abstract
  142. Islet transplantation stabilizes hemostatic abnormalities and cerebral metabolism in individuals with type 1 diabetes. Diabetes Care. 2014; 37(1):267-76. View Abstract
  143. Serine protease inhibitor 6 plays a critical role in protecting murine granzyme B-producing regulatory T cells. J Immunol. 2013 Sep 01; 191(5):2319-27. View Abstract
  144. B7h (ICOS-L) maintains tolerance at the fetomaternal interface. Am J Pathol. 2013 Jun; 182(6):2204-13. View Abstract
  145. CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival. PLoS One. 2013; 8(4):e60391. View Abstract
  146. Effect of the purinergic inhibitor oxidized ATP in a model of islet allograft rejection. Diabetes. 2013 May; 62(5):1665-75. View Abstract
  147. Prolonged, low-dose anti-thymocyte globulin, combined with CTLA4-Ig, promotes engraftment in a stringent transplant model. PLoS One. 2013; 8(1):e53797. View Abstract
  148. Long-term heart transplant survival by targeting the ionotropic purinergic receptor P2X7. Circulation. 2013 Jan 29; 127(4):463-75. View Abstract
  149. 31P-magnetic resonance spectroscopy (31P-MRS) detects early changes in kidney high-energy phosphate metabolism during a 6-month Valsartan treatment in diabetic and non-diabetic kidney-transplanted patients. Acta Diabetol. 2012 Dec; 49 Suppl 1:S133-9. View Abstract
  150. B-cell depletion improves islet allograft survival with anti-CD45RB. Cell Transplant. 2014 Jan; 23(1):51-8. View Abstract
  151. Can existing drugs approved for other indications retard renal function decline in patients with type 1 diabetes and nephropathy? Semin Nephrol. 2012 Sep; 32(5):437-44. View Abstract
  152. Vascular stem and progenitor cells in diabetic complications. Exp Diabetes Res. 2012; 2012:580343. View Abstract
  153. Regenerative therapies for diabetic microangiopathy. Exp Diabetes Res. 2012; 2012:916560. View Abstract
  154. The novel therapeutic effect of phosphoinositide 3-kinase-? inhibitor AS605240 in autoimmune diabetes. Diabetes. 2012 Jun; 61(6):1509-18. View Abstract
  155. Strategies to reverse endothelial progenitor cell dysfunction in diabetes. Exp Diabetes Res. 2012; 2012:471823. View Abstract
  156. [Novel immunological aspects of pediatric kidney transplantation]. G Ital Nefrol. 2012 Jan-Feb; 29(1):44-8. View Abstract
  157. Modified CD4(+) T-cell response in recipients of old cardiac allografts. Transpl Int. 2012 Mar; 25(3):328-36. View Abstract
  158. Near normalization of metabolic and functional features of the central nervous system in type 1 diabetic patients with end-stage renal disease after kidney-pancreas transplantation. Diabetes Care. 2012 Feb; 35(2):367-74. View Abstract
  159. Inotuzumab ozogamicin murine analog-mediated B-cell depletion reduces anti-islet allo- and autoimmune responses. Diabetes. 2012 Jan; 61(1):155-65. View Abstract
  160. IL-21 is an antitolerogenic cytokine of the late-phase alloimmune response. Diabetes. 2011 Dec; 60(12):3223-34. View Abstract
  161. Kidney-pancreas transplantation is associated with near-normal sexual function in uremic type 1 diabetic patients. Transplantation. 2011 Oct 15; 92(7):802-8. View Abstract
  162. Impact of islet transplantation on diabetes complications and quality of life. Curr Diab Rep. 2011 Oct; 11(5):355-63. View Abstract
  163. Immunological applications of stem cells in type 1 diabetes. Endocr Rev. 2011 Dec; 32(6):725-54. View Abstract
  164. Kidney-derived mesenchymal stromal cells modulate dendritic cell function to suppress alloimmune responses and delay allograft rejection. Transplantation. 2010 Dec 27; 90(12):1307-11. View Abstract
  165. Targeting the CXCR4-CXCL12 axis mobilizes autologous hematopoietic stem cells and prolongs islet allograft survival via programmed death ligand 1. J Immunol. 2011 Jan 01; 186(1):121-31. View Abstract
  166. Improved function of circulating angiogenic cells is evident in type 1 diabetic islet-transplanted patients. Am J Transplant. 2010 Dec; 10(12):2690-700. View Abstract
  167. Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes. Diabetes. 2010 Dec; 59(12):3139-47. View Abstract
  168. A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice. Diabetes. 2010 Sep; 59(9):2253-64. View Abstract
  169. The mobilization and effect of endogenous bone marrow progenitor cells in diabetic wound healing. Cell Transplant. 2010; 19(11):1369-81. View Abstract
  170. Liver focal fatty changes at ultrasound after islet transplantation: an early sign of altered graft function? Diabet Med. 2010 Aug; 27(8):960-4. View Abstract
  171. The anti-LFA-1 trial in islet transplantation. Am J Transplant. 2010 Aug; 10(8):1725-6. View Abstract
  172. beta-Cells step up in controlling the autoimmune response. Diabetes. 2010 Aug; 59(8):1861-4. View Abstract
  173. Immunological and regenerative properties of cord blood stem cells. Clin Immunol. 2010 Sep; 136(3):309-22. View Abstract
  174. Proteomics reveals novel oxidative and glycolytic mechanisms in type 1 diabetic patients' skin which are normalized by kidney-pancreas transplantation. PLoS One. 2010 Mar 29; 5(3):e9923. View Abstract
  175. Kidney-pancreas transplantation does not improve retinal arterial flow velocities in type 1 diabetic uremic patients. Transplantation. 2010 Jan 27; 89(2):261-3. View Abstract
  176. Laser capture microdissection as a new tool to assess graft-infiltrating lymphocytes gene profile in islet transplantation. Cell Transplant. 2009; 18(8):827-32. View Abstract
  177. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol. 2009 Jul 15; 183(2):993-1004. View Abstract
  178. B cell-targeted therapies in autoimmunity: rationale and progress. F1000 Biol Rep. 2009 May 28; 1:39. View Abstract
  179. Dimethylarginines in complicated type 1 diabetes: roles of insulin, glucose, and oxidative stress. Free Radic Biol Med. 2009 Aug 01; 47(3):307-11. View Abstract
  180. Divergent role of donor dendritic cells in rejection versus tolerance of allografts. J Am Soc Nephrol. 2009 Mar; 20(3):535-44. View Abstract
  181. The clinical impact of islet transplantation. Am J Transplant. 2008 Oct; 8(10):1990-7. View Abstract
  182. Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes. 2008 Nov; 57(11):3013-24. View Abstract
  183. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes. 2008 Jul; 57(7):1759-67. View Abstract
  184. Phenotypic and functional differences between wild-type and CCR2-/- dendritic cells: implications for islet transplantation. Transplantation. 2008 Apr 15; 85(7):1030-8. View Abstract
  185. CD22 to cure type 1 diabetes. 2008. View Abstract
  186. ?Wound healing kinetics of the genetically diabetic mouse. Wounds. 2008 Jan; 20(1):18-28. View Abstract
  187. Metabolic and immunological features of the failing islet-transplanted patient. Diabetes Care. 2008 Mar; 31(3):436-8. View Abstract
  188. Pancreatic islet cell transplant for treatment of diabetes. Endocrinol Metab Clin North Am. 2007 Dec; 36(4):999-1013; ix. View Abstract
  189. Importance of donor- and recipient-derived selectins in cardiac allograft rejection. J Am Soc Nephrol. 2007 Nov; 18(11):2929-36. View Abstract
  190. Role of ICOS pathway in autoimmune and alloimmune responses in NOD mice. Clin Immunol. 2008 Feb; 126(2):140-7. View Abstract
  191. Evaluation of polyneuropathy markers in type 1 diabetic kidney transplant patients and effects of islet transplantation: neurophysiological and skin biopsy longitudinal analysis. Diabetes Care. 2007 Dec; 30(12):3063-9. View Abstract
  192. Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin Immunol. 2007 Oct; 125(1):16-25. View Abstract
  193. Beta 3 integrins regulate lymphocyte migration and cytokine responses in heart transplant rejection. Am J Transplant. 2007 May; 7(5):1080-90. View Abstract
  194. Altered kidney graft high-energy phosphate metabolism in kidney-transplanted end-stage renal disease type 1 diabetic patients: a cross-sectional analysis of the effect of kidney alone and kidney-pancreas transplantation. Diabetes Care. 2007 Mar; 30(3):597-603. View Abstract
  195. Characterization of donor dendritic cells and enhancement of dendritic cell efflux with CC-chemokine ligand 21: a novel strategy to prolong islet allograft survival. Diabetes. 2007 Apr; 56(4):912-20. View Abstract
  196. Kidney function after islet transplant alone in type 1 diabetes: impact of immunosuppressive therapy on progression of diabetic nephropathy. Diabetes Care. 2007 May; 30(5):1150-5. View Abstract
  197. Early increase of retinal arterial and venous blood flow velocities at color Doppler imaging in brittle type 1 diabetes after islet transplant alone. Transplantation. 2006 May 15; 81(9):1274-7. View Abstract
  198. Role of CXC chemokine receptor 3 pathway in renal ischemic injury. J Am Soc Nephrol. 2006 Mar; 17(3):716-23. View Abstract
  199. Cardiovascular benefits of simultaneous pancreas-kidney transplant versus kidney alone transplant in diabetic patients. Transplant Proc. 2005 Oct; 37(8):3570-1. View Abstract
  200. Cross-sectional assessment of the effect of kidney and kidney-pancreas transplantation on resting left ventricular energy metabolism in type 1 diabetic-uremic patients: a phosphorous-31 magnetic resonance spectroscopy study. J Am Coll Cardiol. 2005 Sep 20; 46(6):1085-92. View Abstract
  201. Morphological and functional differences in haemostatic axis between kidney transplanted and end-stage renal disease patients. Transpl Int. 2005 Sep; 18(9):1036-47. View Abstract
  202. Multivariate analysis of factors affecting patient and graft survival after renal transplant. Transplant Proc. 2005 Jul-Aug; 37(6):2461-3. View Abstract
  203. Natural history of kidney graft survival, hypertrophy, and vascular function in end-stage renal disease type 1 diabetic kidney-transplanted patients: beneficial impact of pancreas and successful islet cotransplantation. Diabetes Care. 2005 Jun; 28(6):1303-10. View Abstract
  204. Islet transplantation is associated with an improvement of cardiovascular function in type 1 diabetic kidney transplant patients. Diabetes Care. 2005 Jun; 28(6):1358-65. View Abstract
  205. Circulating leptin correlates with left ventricular mass in morbid (grade III) obesity before and after weight loss induced by bariatric surgery: a potential role for leptin in mediating human left ventricular hypertrophy. J Clin Endocrinol Metab. 2005 Jul; 90(7):4087-93. View Abstract
  206. Determination of asymmetric and symmetric dimethylarginines in plasma of hyperhomocysteinemic subjects. Amino Acids. 2005 Jun; 28(4):389-94. View Abstract
  207. Gastrointestinal bleeding from enterically drained transplanted pancreas. Transpl Int. 2005 Mar; 18(3):296-302. View Abstract
  208. Technique, complications, and therapeutic efficacy of percutaneous transplantation of human pancreatic islet cells in type 1 diabetes: the role of US. Radiology. 2005 Feb; 234(2):617-24. View Abstract
  209. Management of papillary microcarcinoma of the thyroid gland. Eur J Surg Oncol. 2004 Dec; 30(10):1104-6. View Abstract
  210. Selective intra-graft apoptosis and down-regulation of lymphocyte bcl-2, iNOs and CD95L expression in kidney-pancreas transplanted patients after anti-Thymoglobulin induction. Transpl Int. 2004 Nov; 17(10):603-8. View Abstract
  211. Apoptotic/mytogenic pathways during human heart development. Int J Cardiol. 2004 Sep; 96(3):409-17. View Abstract
  212. Normalization of multiple hemostatic abnormalities in uremic type 1 diabetic patients after kidney-pancreas transplantation. Diabetes. 2004 Sep; 53(9):2291-300. View Abstract
  213. [Simultaneous pancreas-kidney transplantation: a single center experience on 148 cases]. Ann Ital Chir. 2004 Sep-Oct; 75(5):541-6. View Abstract
  214. Correlation between non-reversible thallium-201 myocardial perfusion defect and ECG criteria in the diagnosis of apical myocardial infarction. Int J Cardiol. 2004 Jun; 95(2-3):251-4. View Abstract
  215. Long-term survival after kidney and kidney-pancreas transplantation in diabetic patients. Transplant Proc. 2004 May; 36(4):1072-5. View Abstract
  216. L-arginine-induced vasodilation of the renal vasculature is preserved in uremic type 1 diabetic patients after kidney and pancreas but not after kidney-alone transplantation. Diabetes Care. 2004 Apr; 27(4):947-54. View Abstract
  217. Simultaneous pancreas-kidney transplantation: short- and long-term results. Transplant Proc. 2004 Apr; 36(3):586-8. View Abstract
  218. Islet transplantation is associated with improvement of renal function among uremic patients with type I diabetes mellitus and kidney transplants. J Am Soc Nephrol. 2003 Aug; 14(8):2150-8. View Abstract
  219. Successful endovascular treatment for gastroduodenal artery pseudoaneurysm with an arteriovenous fistula after pancreas transplantation. Transpl Int. 2003 Sep; 16(9):694-6. View Abstract
  220. Molecular pathways involved in the antineoplastic effects of calcitriol on insulinoma cells. Endocrinology. 2003 May; 144(5):1832-41. View Abstract
  221. Islet transplantation improves vascular diabetic complications in patients with diabetes who underwent kidney transplantation: a comparison between kidney-pancreas and kidney-alone transplantation. Transplantation. 2003 Apr 27; 75(8):1296-301. View Abstract
  222. Long-term beneficial effect of islet transplantation on diabetic macro-/microangiopathy in type 1 diabetic kidney-transplanted patients. Diabetes Care. 2003 Apr; 26(4):1129-36. View Abstract
  223. Diagnosis and treatment of familial papillary thyroid carcinoma. Endocrinochirurgia: Verso il millenio. 2003; 235-242. View Abstract
  224. A report of six cases of familial papillary thyroid cancer. Eur J Surg Oncol. 2003 Mar; 29(2):185-7. View Abstract
  225. Successful surgical salvage of pancreas allograft. Transplantation. 2003 Jan 27; 75(2):233-6. View Abstract
  226. Secretory defects induced by immunosuppressive agents on human pancreatic beta-cells. Acta Diabetol. 2002 Dec; 39(4):229-33. View Abstract
  227. Antitumorigenic and antiinsulinogenic effects of calcitriol on insulinoma cells and solid beta-cell tumors. Endocrinology. 2002 Oct; 143(10):4018-30. View Abstract
  228. Advantages and disadvantages of enteric versus bladder diversion in simultaneous kidney-pancreas transplantation. Chir Ital. 2002 Jul-Aug; 54(4):429-36. View Abstract
  229. The effects of pancreas transplantation on the course of secondary diabetic complications. Graft. 2002; (5):303-307.. View Abstract
  230. Magnetic resonance image (MRI) of an acquired aorto-pulmonary fistula, associated with cerebral and paradoxical embolism. Int J Cardiol. 2002 Apr; 83(1):85-6. View Abstract
  231. Urological complications after simultaneous renal and pancreatic transplantation. Eur J Surg. 2002; 168(11):609-13. View Abstract
  232. Cardiovascular outcomes after kidney-pancreas and kidney-alone transplantation. Kidney Int. 2001 Nov; 60(5):1964-71. View Abstract
  233. Wie effectiv ist pancreas transplant. Transplant Link. 2001; 46-52. . View Abstract
  234. Effects of kidney-pancreas transplantation on atherosclerotic risk factors and endothelial function in patients with uremia and type 1 diabetes. Diabetes. 2001 Mar; 50(3):496-501. View Abstract
  235. Persistent ST segment elevation in a patient with metastatic involvement of the heart. Minerva Cardioangiol. 2001 Feb; 49(1):81-5. View Abstract
  236. Reversal of left ventricular diastolic dysfunction after kidney-pancreas transplantation in type 1 diabetic uremic patients. Diabetes Care. 2000 Dec; 23(12):1804-10. View Abstract
  237. Patient survival and cardiovascular events after kidney-pancreas transplantation: comparison with kidney transplantation alone in uremic IDDM patients. Cell Transplant. 2000 Nov-Dec; 9(6):929-32. View Abstract
  238. ECG mimicking acute myocardial infarction during heart involvement by lung neoplasm. Int J Cardiol. 2000 Jul 31; 74(2-3):225-6. View Abstract
  239. Reversibilità della disfunzione diastolica, endoteliale e della macroangiopatia. Ruolo dell’euglicemia indotta da trapianto di pancreas. Parma Diabete . 2000; 28-37. View Abstract
  240. Soluble antiapoptotic molecules and immune activation in chronic heart failure and unstable angina pectoris. J Clin Immunol. 2000 Mar; 20(2):101-6. View Abstract
  241. Disruption of nocturnal melatonin rhythm and immunological involvement in ischaemic stroke patients. Scand J Immunol. 1999 Aug; 50(2):228-31. View Abstract
  242. 35th Annual Meeting of the European Association for the Study of Diabetes : Brussels, Belgium, 28 September-2 October 1999. Diabetologia. 1999 Aug; 42(Suppl 1):A1-A330. View Abstract
  243. Coronary occlusion after recurrent myocardial perfusion abnormalities in a Young SLE patient. J Cardiovascular Diagnosis and Procedures. 1999; 16(2):32-36. View Abstract
  244. Cardiac Troponin T to evaluate myocardial protection via intermittent cold blood or continuous warm blood cardioplegia in coronary artery bypass grafting. J Cardiovasc Surg (Torino). 1998 Dec; 39(6):797-802. View Abstract
  245. Plasma homocysteine and folate are related to arterial blood pressure in type 2 diabetes mellitus. Am J Hypertens. 1998 Sep; 11(9):1100-7. View Abstract
  246. Fasting and post-methionine load homocyst(e)ine values are correlated with microalbuminuria and could contribute to worsening vascular damage in non-insulin-dependent diabetes mellitus patients. Metabolism. 1998 Aug; 47(8):915-21. View Abstract
  247. Cardiovascular disease and neoplasms after pancreas transplantation. Lancet. 1998 Jul 04; 352(9121):65; author reply 66. View Abstract
  248. [Doppler echocardiographic study of left ventricular function in patients with systemic lupus erythematosus]. Cardiologia. 1997 Nov; 42(11):1179-83. View Abstract
  249. Myocarditis due to Legionella Pneumophila: a case report . Journal of Cardiovascular Diagnosis and Procedures. 1997; 14:177-179. View Abstract
  250. Isolated and preclinical impairment of left ventricular filling in insulin-dependent and non-insulin-dependent diabetic patients. Clin Cardiol. 1997 Jun; 20(6):536-40. View Abstract
  251. Diastolic impairment in asymptomatic systemic lupus erythematosus patients. Clin Rheumatol. 1997 May; 16(3):320-1. View Abstract
  252. Left ventricular function in insulin-dependent and in non-insulin-dependent diabetic patients: radionuclide assessment. Cardiology. 1997 Mar-Apr; 88(2):152-5. View Abstract
  253. [Myocarditis in legionellosis. A case report]. Minerva Cardioangiol. 1996 Sep; 44(9):429-31. View Abstract
  254. Miocardite in corso di Legionellosi . Minerva Cardioangiologica. 1996; 44:429-31. View Abstract
  255. Myocardial indium-111 antimyosin uptake after uncomplicated coronary artery bypass surgery. Int J Cardiol. 1996 Aug; 55(3):239-44. View Abstract
  256. Perioperative myocardial cell damage assessed by immunoradiometric assay of beta-myosin heavy chain serum levels in patients undergoing coronary bypass surgery. Int J Cardiol. 1996 Jul 26; 55(2):157-62. View Abstract
  257. Diagnosi di tromboembolia polmonare mediante ecocardiografia transesofagea. Minerva Cardioangiologica. 1996; 44:369-372.. View Abstract
  258. Impaired nocturnal melatonin excretion and changes of immunological status in ischaemic stroke patients. Lancet. 1996 Mar 09; 347(9002):692-3. View Abstract

Contact Paolo Fiorina

Phone: 617-919-2624
Print Profile